Skip to content

The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens

The pen in your fridge is the product of a century of injection-device development. How GLP-1 delivery devices evolved, which brands use vials, multi-dose pens or single-dose auto-injectors, why pens are easier and safer than vials, and how auto-injectors differ from dial-a-dose pens.

Updated Sep 26, 2026Evidence-backed

The pen in your fridge has a longer backstory than the medication inside it: nearly a century of injection-device engineering, inherited almost entirely from insulin. Knowing that history makes it easier to see why your device works the way it does, and what actually separates an auto-injector from a dial-a-dose pen.

Injection devices didn't start with GLP-1s

The pens used for semaglutide and tirzepatide descend from delivery devices first built for insulin. A historical review of insulin delivery traces the path from the vial and syringe, used since insulin was first given as a treatment in 1921, to the first pen injectors and then to the disposable and reusable pens refined over the following decades (Fry, Journal of Diabetes Science and Technology, 2012, DOI (external link)). Pens were developed to ease the practical burdens of vials: carrying several components, drawing up doses accurately, and handling a bare needle. Designs have kept changing since to cut user error and make injections easier. GLP-1 pens inherited that lineage, which is why the devices below will look familiar to anyone who has used an insulin pen.

The three kinds of device you'll see

Vial and syringe. You draw the medication from a vial into a syringe before each injection. This is how most compounded GLP-1 products are supplied. Branded vials exist too: Zepbound and Mounjaro are also sold in single-dose vials and in multi-dose vials that hold 4 doses.

Multi-dose pens. A pre-filled pen that holds several doses. You screw on a new needle each time, set the dose, insert the needle and press the button. Some let you dial a range of doses from one pen: Saxenda's pen delivers 0.6, 1.2, 1.8, 2.4 or 3 mg. Others hold four doses of one strength, such as the Ozempic pens, the Zepbound and Mounjaro KwikPen, and the Wegovy FlexTouch 2.4 mg pen.

Single-dose auto-injectors. A pre-set pen used once. The needle stays hidden, and pressing the pen against your skin and holding the button does the whole injection, with nothing to dial. Wegovy, Zepbound, Mounjaro and Trulicity all come as single-dose pens, and their pens cover every step of the dose ladder, from the starting dose to the maximum.

Why pens and auto-injectors are easier than a vial

A pre-set pen takes away the step where most vial errors happen: working out how much liquid to draw from the vial's concentration. That step is a known problem. The FDA has warned about patients drawing 5 to 20 times their intended dose from compounded vials, as our guide on compounded dosing: vials vs. pens explains.

A vial also means more steps where something can go wrong: drawing air, turning the vial over, drawing the right volume, clearing bubbles, then injecting. A single-dose auto-injector cuts that to uncapping, pressing and holding. In a manufacturer-funded study of 211 people with type 2 diabetes who had never injected before, 99.1% used the dulaglutide (Trulicity) single-dose pen, filled with placebo, successfully by their final injection, and more than 96% found it easy to use (Matfin et al., J Diabetes Sci Technol, 2015, DOI (external link)).

Auto-injectors also keep the needle hidden before, during and after the injection, which helps with needle anxiety and lowers the chance of a needle-stick. Used pens and needles still need proper sharps disposal. And a single-use pen means no separate vials, syringes and needles to carry, and no repeated punctures of the same vial.

Auto-injectors vs. multi-dose pens

Each design makes a different trade:

Multi-dose pensSingle-dose auto-injectors
Dose flexibilityDial pens can deliver a range of doses from one pen; fixed-dose multi-dose pens can'tOne set dose per pen; a new strength means a new pen
StepsMore: attach needle, set dose, insert and pressFewer: uncap, press and hold
NeedleVisible when you attach it and injectHidden throughout

A dial pen gives you flexibility while your dose is still changing. An auto-injector is simpler and has fewer steps to get wrong. Which one you get usually depends on your medication and brand more than on your own choice, but if you have a preference it's worth asking your prescriber or pharmacist, since several brands now come in more than one format.

Technique still matters

Whatever device you use, good technique still counts: prime the pen when its instructions say to, check the dose or pen strength before you inject, and rotate injection sites. Our guide on pen types and injection technique covers the details.

Study findings above are attributed to their authors and were located via PubMed.

This article is for general education and is not medical advice. Decisions about your specific device and treatment belong with your prescriber.

autoinjectorpenhistorydosingdevice

Was this helpful?

Common questions

Questions people often ask about this topic.

  • What's the difference between an auto-injector and a dial-a-dose pen?

    An auto-injector is pre-set to one dose, keeps the needle hidden, and does the whole injection when you press and hold. A dial pen needs you to attach a needle, dial the dose, insert the needle and press, but one pen can deliver a range of doses. Neither is better for everyone: dial pens are flexible while your dose is changing, and auto-injectors are simpler once it's set.

  • Why are auto-injector pens considered safer than vials and syringes?

    A pre-set pen removes the need to work out a draw-up volume from a vial's concentration, which is where the FDA has documented serious dosing errors, particularly with compounded products. It also keeps the needle hidden before, during and after the injection, has fewer steps that could be skipped or done wrong, and saves you from carrying and managing separate vials, syringes and needles.

  • Were injection pens invented for GLP-1 medications?

    No. The pens used for semaglutide and tirzepatide descend from nearly a century of injection devices first developed for insulin, going back to vial-and-syringe use in 1921. Pen injectors were developed to ease the burdens of vials: carrying several components, drawing up doses accurately, and handling a bare needle.

  • Can I choose which type of pen I get for my GLP-1?

    It depends mostly on your medication and brand. Wegovy, Zepbound, Mounjaro and Trulicity come as single-dose auto-injectors, Saxenda and Victoza use dial pens, Ozempic uses multi-dose pens, and Zepbound and Mounjaro are also sold as vials and as a 4-dose KwikPen. If you have a preference, ask your prescriber or pharmacist which formats your drug comes in.

  • Does injection technique still matter with an auto-injector?

    Yes. Whatever device you use, good technique still counts: priming when the instructions call for it, checking the dose or pen strength before you inject, and rotating injection sites. The device removes error-prone steps, but it doesn't replace careful use.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

5Supporting

Revision history

Last updated · 4 revisions recorded.

Show what changed
  1. v4

    Evidence sources 1 → 5

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • U-100 insulin syringe (units) — A syringe marked in "units" where 100 units equal 1 mL — designed for U-100 insulin but commonly used to draw compounded GLP-1 doses from vials.
    • Lowest effective dose — The smallest dose of a medication that produces the intended benefit with tolerable side effects. It is a standard prescribing principle.

    Related guides

    • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
    • Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found — If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that, and Wegovy users also have an on-label switch to Wegovy tablets. This guide covers what the trial found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.
    • Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show — Some people space their weekly GLP-1 to every 10 or 14 days to save money or ease off. This guide covers what that does to drug levels, what the two small studies found, why that isn't proof yet, and the risks worth planning around with a prescriber.
    • What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026 — The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. It names GLP-1s as the preferred obesity medication in type 2 diabetes, sets realistic weight-loss targets, and says the highest dose isn't always the goal. The headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.